CN101330919B - 包含(e)-7-[4-(4-氟苯基)-6-异丙基-2-[甲基(甲磺酰基)氨基]嘧啶-5-基]-(3r,5s)-3,5-二羟基庚-6-烯酸的药物组合物 - Google Patents

包含(e)-7-[4-(4-氟苯基)-6-异丙基-2-[甲基(甲磺酰基)氨基]嘧啶-5-基]-(3r,5s)-3,5-二羟基庚-6-烯酸的药物组合物 Download PDF

Info

Publication number
CN101330919B
CN101330919B CN2006800476115A CN200680047611A CN101330919B CN 101330919 B CN101330919 B CN 101330919B CN 2006800476115 A CN2006800476115 A CN 2006800476115A CN 200680047611 A CN200680047611 A CN 200680047611A CN 101330919 B CN101330919 B CN 101330919B
Authority
CN
China
Prior art keywords
pharmaceutical composition
fluorophenyl
isopropyl
methyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2006800476115A
Other languages
English (en)
Chinese (zh)
Other versions
CN101330919A (zh
Inventor
M·T·杰克里克
K·纳沃斯尼科
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lek Pharmaceuticals dd
Original Assignee
Lek Pharmaceuticals dd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lek Pharmaceuticals dd filed Critical Lek Pharmaceuticals dd
Publication of CN101330919A publication Critical patent/CN101330919A/zh
Application granted granted Critical
Publication of CN101330919B publication Critical patent/CN101330919B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2006800476115A 2005-12-20 2006-12-18 包含(e)-7-[4-(4-氟苯基)-6-异丙基-2-[甲基(甲磺酰基)氨基]嘧啶-5-基]-(3r,5s)-3,5-二羟基庚-6-烯酸的药物组合物 Expired - Fee Related CN101330919B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SI200500344 2005-12-20
SIP200500344 2005-12-20
PCT/EP2006/012180 WO2007071357A2 (en) 2005-12-20 2006-12-18 Pharmaceutical composition comprising (e) -7- [4- (4-fluorophenyl) -6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin-5 -yl- (3r, 5s) -3, 5-dihydr0xyhept-6-en0ic acid

Publications (2)

Publication Number Publication Date
CN101330919A CN101330919A (zh) 2008-12-24
CN101330919B true CN101330919B (zh) 2012-12-05

Family

ID=37866173

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006800476115A Expired - Fee Related CN101330919B (zh) 2005-12-20 2006-12-18 包含(e)-7-[4-(4-氟苯基)-6-异丙基-2-[甲基(甲磺酰基)氨基]嘧啶-5-基]-(3r,5s)-3,5-二羟基庚-6-烯酸的药物组合物

Country Status (9)

Country Link
US (1) US20090093499A1 (enExample)
EP (1) EP1968593B1 (enExample)
JP (1) JP5235676B2 (enExample)
CN (1) CN101330919B (enExample)
AU (1) AU2006329006B2 (enExample)
BR (1) BRPI0620629B8 (enExample)
CA (1) CA2630704C (enExample)
EA (1) EA015682B1 (enExample)
WO (1) WO2007071357A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008036286A1 (en) 2006-09-18 2008-03-27 Teva Pharmaceutical Industries Ltd. Crystalline rosuvastatin calcium
EP2285353A1 (en) * 2008-01-30 2011-02-23 Lupin Limited Modified release formulations of hmg coa reductase inhibitors
EP2138165A1 (en) 2008-06-27 2009-12-30 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising a statin
HRP20180077T1 (hr) * 2008-06-27 2018-02-23 Krka, Tovarna Zdravil D.D., Novo Mesto Farmaceutski sastav koji sadrži statin
PL386051A1 (pl) * 2008-09-09 2010-03-15 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Stabilna doustna kompozycja farmaceutyczna zawierająca farmaceutycznie dopuszczalną sól kwsu [(E)-7-[4-(4-fluorofenylo)-6-izopropylo-2-[metylo(metylosulfonylo)amino]pirymidyn-5-ylo] (3R,5S)-3,5-dihydroksyhept-6-enowego
TR200902077A2 (tr) 2009-03-17 2010-01-21 Sanovel İlaç San.Veti̇c.A.Ş. Stabil rosuvastatin kompozisyonları
RU2606592C1 (ru) * 2015-10-07 2017-01-10 Открытое Акционерное Общество "Татхимфармпрепараты" Фармацевтическая композиция, содержащая кальциевую соль розувастатина (варианты)
AU2020417043A1 (en) * 2019-12-31 2022-06-09 Pfizer Inc. Stable immediate release tablet and capsule formulations of 1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
GB0000710D0 (en) * 1999-02-06 2000-03-08 Zeneca Ltd Drug combination
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
US6399101B1 (en) * 2000-03-30 2002-06-04 Mova Pharmaceutical Corp. Stable thyroid hormone preparations and method of making same
EP1368000A4 (en) * 2001-03-13 2004-12-01 Penwest Pharmaceuticals Co CHRONOTHERAPEUTIC PHARMACEUTICAL FORMS CONTAINING A GLUCOCORTICOSTEROID
SE0101329D0 (sv) * 2001-04-12 2001-04-12 Astrazeneca Ab Pharmaceutical formulation
GB0111077D0 (en) * 2001-05-04 2001-06-27 Biochemie Gmbh Organic compounds
US20030215502A1 (en) * 2002-03-20 2003-11-20 Elan Pharma International Limited Fast dissolving dosage forms having reduced friability
WO2003090723A1 (en) * 2002-04-23 2003-11-06 Bristol-Myers Squibb Company Modified-release vasopeptidase inhibitor formulation, combinations and method
CA2483099A1 (en) * 2002-05-03 2003-11-13 Hexal Ag Stable pharmaceutical formulation for a combination of a statin and an ace inhibitor
SI21402A (sl) * 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
WO2005040134A1 (en) * 2003-10-22 2005-05-06 Ranbaxy Laboratories Limited Process for the preparation of amorphous rosuvastatin calcium
US8987322B2 (en) * 2003-11-04 2015-03-24 Circ Pharma Research And Development Limited Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
CA2546894C (en) * 2003-12-02 2009-09-08 Teva Pharmaceutical Industries Ltd. Reference standard for characterization of rosuvastatin
EP1737828A1 (en) * 2004-01-19 2007-01-03 Ranbaxy Laboratories Limited Amorphous magnesium salts of rosuvastatin
EP1709008A1 (en) * 2004-01-19 2006-10-11 Ranbaxy Laboratories Limited Salts of hmg-coa reductase inhibitors and use thereof

Also Published As

Publication number Publication date
CA2630704C (en) 2014-08-19
AU2006329006A1 (en) 2007-06-28
WO2007071357A2 (en) 2007-06-28
BRPI0620629B8 (pt) 2021-05-25
JP2009519985A (ja) 2009-05-21
BRPI0620629B1 (pt) 2020-01-14
CN101330919A (zh) 2008-12-24
BRPI0620629A2 (pt) 2011-11-16
WO2007071357A3 (en) 2007-11-08
JP5235676B2 (ja) 2013-07-10
US20090093499A1 (en) 2009-04-09
EA015682B1 (ru) 2011-10-31
CA2630704A1 (en) 2007-06-28
EA200801447A1 (ru) 2008-12-30
EP1968593B1 (en) 2017-08-23
AU2006329006B2 (en) 2013-02-28
EP1968593A2 (en) 2008-09-17

Similar Documents

Publication Publication Date Title
FI111806B (fi) Farmaseuttisia koostumuksia
US6306436B1 (en) Stabilized, acid-free formulation for sustained release of bupropion hydrochloride
AU2006250340B2 (en) Pharmaceutical composition
WO2009101940A1 (ja) 溶出性の改善された錠剤
CA2651138C (en) Pharmaceutical composition
WO2016136849A1 (ja) 固形製剤
TWI811195B (zh) 包含兩種不同活性原料的醫藥組成物及其製備方法
CN101330919B (zh) 包含(e)-7-[4-(4-氟苯基)-6-异丙基-2-[甲基(甲磺酰基)氨基]嘧啶-5-基]-(3r,5s)-3,5-二羟基庚-6-烯酸的药物组合物
TW201707702A (zh) 一種含有喹啉衍生物或其鹽的醫藥組成物
JP2009519985A5 (enExample)
JP6765473B2 (ja) オルメサルタンのプロドラッグ製剤
JPWO2011099573A1 (ja) 徐放性製剤
JP2017095441A (ja) アジルサルタン含有医薬組成物、医薬組成物におけるアジルサルタンの安定化方法、及びアジルサルタンの安定化剤
US20250134841A1 (en) Pharmaceutical composition of bempedoic acid
CN110913843A (zh) 药物组合物
WO2025186786A1 (en) Oral pharmaceutical composition of pitavastatin and ezetimibe, method and uses thereof
MX2008008192A (en) Pharmaceutical composition comprising (e) -7- [4- (4-fluorophenyl) -6-isopropyl-2- [methyl (methylsulfonyl) amino]pyrimidin-5 -yl- (3r, 5s) -3, 5-dihydr0xyhept-6-en0ic acid
JP2017132724A (ja) アムロジピン含有被覆造粒物を含む配合口腔内崩壊錠
JP2021116284A (ja) エゼチミブおよびアトルバスタチン含有医薬組成物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20121205

Termination date: 20211218